Objective To compare fetal microchimerism (FMc) in pregnancies with uncomplicated vaginal delivery (VD) versus caesarean delivery (CD).
Introduction
Bidirectional maternal-fetal transfer of cells and DNA occurs early in pregnancy and continues throughout gestation. 1 Fetal cells in maternal circulation and tissues, predominantly transferred transplacentally, can be present as microchimerism (Mc) and have the potential to persist for decades. [2] [3] [4] [5] Obstetric factors seem to influence the amount of Mc transferred. In miscarriage and abortion, fetal Mc (FMc) transfer to the mother is higher among participants undergoing surgical treatment versus those treated medically. 6 Pregnancies characterised by placental dysfunction are also known to have altered fetal-maternal exchange, with pregnancies affected by pre-eclampsia demonstrating greater amounts of FMc in maternal circulation. 7, 8 Longterm persistence of naturally acquired cellular Mc is known to occur, and many questions regarding the role of FMc in maternal post-reproductive health remain unanswered. [9] [10] [11] Epidemiological data suggest that the mode of delivery may be an important factor for health in later life of both the mother and neonate. Several population-based studies demonstrate that caesarean delivery (CD), compared with vaginal delivery (VD), is a risk factor for the development of childhood autoimmune diseases, including type 1 diabetes and inflammatory bowel disease. 12, 13 Though less is known about the association of mode of delivery with subsequent maternal health, one large retrospective study analysed the relationship of delivery mode with subsequent autoimmune disease (AID) in a Danish healthcare database (> 1 million women). Compared with nulliparous women, the incidence of AID diagnosis was significantly greater in the first year after delivery and was higher in those who underwent a CD versus VD.
14 Because FMc is associated with certain AID, 15 the authors of this study speculated that a greater amount of fetomaternal interface disruption may occur during CD compared with VD, allowing for greater cellular transfer. 16 Because obstetric factors, including mode of delivery, may impact FMc transfer to the mother with potential long-term implications, we sought to evaluate FMc transfer at VD versus CD in women with uncomplicated deliveries.
Methods
We conducted a prospective cohort study of participants anticipated and subsequently confirmed to have an uncomplicated delivery of a pregnancy without pertinent complications. We included women ≥ 18 years old carrying a nonanomalous singleton fetus. Women with the following conditions were excluded because these conditions may affect FMc detection or transfer at the time of delivery: multiple gestation, conception via in vitro fertilisation, pre-eclampsia, HELLP (haemolysis, elevated liver enzymes, low platelets) syndrome, eclampsia, fetal growth restriction (estimated fetal weight < 10th centile), external cephalic version in the current pregnancy, placental abnormalities (invasive placentation, placenta praevia, placental abruption), preterm labour, and maternal autoimmune disease or transplant. Women with pregestational and gestational diabetes were permitted to enrol in the study if their delivery was confirmed to be uncomplicated. Gestational age was determined by the last menstrual period corroborated by a first-or second-trimester ultrasound or the earliest ultrasound available. Mode of delivery was characterised as either VD (spontaneous and operative) or CD (scheduled and unscheduled). Initial chart review confirmed that participants were eligible for enrolment. Following delivery and collection of samples, additional detailed prenatal, intrapartum and postpartum characteristics were reviewed to confirm an uncomplicated course for continued inclusion in the study.
Sample collection and isolation of peripheral blood mononuclear cells
Maternal peripheral blood samples were collected at two time-points: (i) prelabour third trimester (36 0/7 -42 0/7 weeks) and (ii) postdelivery within approximately 2 hours of placental delivery. A cord blood sample was also collected by venepuncture of a doubly clamped section of the umbilical cord from the placenta after delivery. All blood samples were collected in acid citrate dextrose solution A-vacutainer tubes and underwent processing (unfrozen) within 24 hours. The majority of samples were processed within 12 hours. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll Histopaque (Pharmacia Biotech, Uppsala, Sweden) gradient centrifugation at a density of 1.077 g/ml, cryopreserved in dimethyl sulphoxide, and stored in the gas phase of liquid nitrogen. Genomic DNA was extracted from whole blood and PBMC using a QIAmp â DNA Mini Kit (Qiagen, Hilden, Germany) or PureLink â Genomic DNA Mini Kit (Invitrogen, Thermo Fisher Scientific, Carlsbad, CA, USA).
Genotyping of mother-baby pairs
Because of extensive polymorphism in human leucocyte antigen (HLA) genes, HLA genotyping of women and their fetuses usually results in identification of a polymorphism unique to the fetus that can be targeted by quantitative polymerase chain reaction (qPCR) to identify and quantify FMc. HLA genotyping was conducted using a Luminex-based (One Lambda; Thermo Fisher Scientific) PCR-sequence-specific oligonucleotide probe-based technique. Maternal and cord blood samples were HLA genotyped for the class II loci DRB1, DQA1 and DQB1. HLA relationships were then examined to identify non-shared HLA polymorphisms targetable to identify FMc. Because an HLA polymorphism unique to the fetus may not always be available for all mother-baby pairs, genotyping for several other polymorphic non-HLA genes was also performed as necessary. These genes included antithrombin III, thyroglobulin, and glutathione S-transferase theta 1.
Genotyping for these non-HLA loci used a conventional PCR system described previously. 17 For maternal-fetal pairs without an HLA or non-HLA polymorphism targetable for FMc and with a male fetus, the SRY gene was used as a target for FMc.
Detection and quantification of FMc
After identifying a polymorphism unique to the neonate, we used the appropriate assay from a panel of qPCR assays previously developed for this purpose to test DNA extracted from maternal PBMC for FMc. 18 Sensitivity of the primers used was previously established by testing of each HLA-specific qPCR primer with an extended panel of well-characterised HLA cell lines. Of note, primers are designed to amplify specific HLA alleles (i.e. amplification of only the DRB1*01 allele group and no other groups such as DRB1*03, 04). Testing is performed on a cell-line known to be positive for the HLA target of interest at increasing concentrations (lowest of 0.5 cell equivalents, highest of 500 cell equivalents) among a background of cells known to be negative for that HLA polymorphism. Six replicates of DNA from PBMC were tested from each blood draw, with total reaction volumes of 50 µl. A calibration curve for the polymorphism-specific assay using commercially available cell lines known to be positive for the HLA target of interest was included to quantify the amount of FMc and to validate the assay for each experiment (positive control). Every sample was also tested for a nonpolymorphic gene, BGLOB. A BGLOB calibration curve [prepared from commercially available human genomic DNA (Promega, Madison, WI, USA)] was concurrently evaluated on each plate to quantify the total number of genome equivalents (gEq) of DNA tested in each reaction. DNA quantities were reported as the DNA gEq number of FMc cells per 100 000 total gEq tested, using a conversion factor of 6.6 pg of DNA per cell. 19 A minimum of 30 000 total gEq tested per sample was assessed.
Multiple precautions were taken to minimise potential for contamination in qPCR experiments. DNA extractions and qPCR preparations were performed under an ultraviolet light-equipped safety hood cleaned with bleach, and filtered tips were used during pipetting. Each experiment included multiple negative control wells to ensure the absence of contamination.
Statistical methods
A sample size calculation for this study has a high degree of uncertainty because preliminary data are limited. However, in our previous study of FMc transfer to maternal circulation in pregnancy loss (≤ 23 6/7 weeks), surgical management was associated with a detection rate ratio of 24.7 for detection of post-treatment FMc compared with medical management. 6 Based on this, inclusion of 18 participants (nine with VD and nine with CD) would be expected to yield 90% power to detect a similar rate ratio difference at an a level of 0.05. Because we anticipated higher overall detection of FMc in the current study (at term versus the earlier gestational age of the previous study), which could diminish differences between groups, we sought to enrol approximately one-third more additional participants for the current study.
Fisher's exact and chi-square analyses were used to compare categorical variables as appropriate. Student's t test or the Mann-Whitney U test was used for comparison of continuous variables. Logistic regression was used to evaluate the association between mode of delivery and FMc detection. Negative binomial regression was used to compare FMc concentration by mode of delivery. The use of negative binomial models for analysis of Mc concentrations has previously been tested and described. 20 Additional covariates were included in the adjusted models if they changed the coefficient for mode of delivery by 10% or more (confounding) or were significantly related to the outcome at the P ≤ 0.10 level (prediction), and included gravidity and gestational age at delivery. Because the total gEq tested is considered a crucially important covariate, this variable was forced into all adjusted models. As delivery is our obstetric event of interest, and fetal cell transfer may have already occurred by late in the third trimester, we also included whether or not a participant was positive for FMc in the predelivery sample in the negative binomial models.
Results
Between August 2014 and May 2016, 74 participants were prospectively recruited and had at least one sample (of the required three) collected. Following initiation of sample collection, 35 participants were excluded because one or more sample collections were missed (n = 29), the participant developed pre-eclampsia (n = 4), placenta praevia was diagnosed (n = 1), or a history of maternal Crohn's disease was discovered (n = 1). After completion of all sample collections and genotyping (n = 39), three mother-baby pairs were excluded given that no HLA or non-HLA assay was informative for a unique FMc target. Ultimately, 36 mother-baby pairs were available for FMc analysis. Of these, 24 underwent VD and 12 underwent CD, including six scheduled CD and six unscheduled CD (combined for primary analysis) (Figure 1 ).
There were no differences in rates of induction of labour or length of labour (only including women who laboured in the CD group) between the groups (Table 1) . Indication for CD included scheduled repeat CD (n = 6), non-reassuring fetal status (n = 2), second-stage arrest (n = 2), first-stage arrest (n = 1), and desire for repeat CD after presenting in labour (n = 1). Labour management and the decision to proceed with CD was at the discretion of the obstetric providers at each delivery hospital. All placentas were delivered spontaneously without the use of manual or instrumented extraction for both VD and CD participants.
There were no differences between the two groups with respect to demographic factors including age, race, earliest recorded body mass index, gravidity, parity, use of tobacco, gestational age at delivery, birthweight, 5-minute Apgar scores, or neonatal sex. The gestational age at which the predelivery sample was collected tended to be slightly later in the CD group, but this difference was not statistically significant. As expected, there was significantly more estimated blood loss in the CD group compared with the VD group. No woman received a blood transfusion antepartum or postpartum. Importantly, there was no significant difference between the groups in the time from placental delivery to postdelivery maternal sample collection (median 96 minutes for VD compared with 53 minutes for CD, P = 0.32) ( Table 1) .
The mean total number of gEq tested for FMc was similar among the predelivery and postdelivery samples for all participants: predelivery VD 139 618 gEq (AE 37 320), postdelivery VD 144 571 gEq (AE 43 553), predelivery CD 149 399 gEq (AE 49 173), and postdelivery CD 142 645 gEq (AE 34 148), P = 0.83.
Fetal microchimerism detection among postdelivery samples was higher in participants following a CD versus VD (58.3% versus 16.7%, P = 0.02). In the unadjusted model, the likelihood of FMc detection in postdelivery samples was sevenfold higher for participants undergoing a CD (odds ratio 7.0, 95% CI 1.4-34.4). After controlling for the total number of gEq tested for each sample, gravidity and gestational age at delivery, the likelihood of postdelivery FMc detection was almost ninefold higher in those participants who had a CD versus VD (adjusted odds ratio 8.8, 95% CI 1.6-47.6, P = 0.01) ( Table 2) .
Analysis of FMc concentration by negative binomial regression to determine quantitative estimates for the detection rate ratio (DRR) of FMc by mode of delivery is also shown in Table 2 . In the unadjusted model, the DRR for FMc in participants who underwent a CD versus VD did not differ significantly (DRR 0.34, 95% CI 0.04-2.7; P = 0.31). However, in the final model, adjusted for total gEq tested, gravidity, gestational age at delivery and predelivery positivity for FMc, the DRR for FMc was higher in the CD group (aDRR 14.7, 95% CI 3.2-66.8; P = 0.001) ( Table 2) . For all participants, FMc concentrations before and after delivery are shown in Figure 2 . Though results from scheduled and unscheduled CDs were combined for analysis, the figure indicates subtypes of CD.
Although we excluded participants with pre-eclampsia or HELLP syndrome, one woman developed mild, transiently elevated blood pressures intrapartum; however, she was not given magnesium sulphate and did not require antihypertensive therapy. Additionally, one woman presented with premature rupture of membranes at 36 3/7 weeks gestation in the absence of labour and underwent labour induction with cervical ripening. Given the overall uncomplicated nature of these participants' deliveries, they were included in our analysis. Repeat analysis after removal of the data for these two participants did not change our results (data not shown).
Discussion

Main findings
In this prospective study of women undergoing uncomplicated deliveries, we found that FMc transfer to maternal circulation was greater following CD than VD. A previous study by our group demonstrated similar findings in pregnancy loss (miscarriages and terminations), with women undergoing a surgical procedure demonstrating higher FMc detection and concentration. 6 These two studies highlight the potential for obstetric treatment-related factors to influence transfer of cellular FMc to the mother. Although the mechanism of increased FMc transfer in CD is unknown, surgical disruption of the maternal-fetal interface may lead to an abrupt showering of FMc into the maternal circulation as the relatively contained maternal-fetal-placental unit does not experience similar interface breaches with a normal VD. Sweeping of the intrauterine cavity during CD, commonly performed at the delivering hospitals, may also account for this difference. Additionally, other differences in uterine involution or immediate postpartum physiology after CD may contribute.
Obstetric events demonstrate transfer of differential FMc amounts 6, 8 and the authors of an epidemiological study propose a potential role for FMc to explain an association with mode of delivery and development of AID.
14 Our study directly demonstrates increased detection and concentration of FMc in postdelivery maternal peripheral blood following CD compared with VD in women with uncomplicated deliveries. CI, confidence interval; DRR, detection rate ratio; FMc, fetal microchimerism; OR, odds ratio; Ref, reference. *Logistic regression model adjusted for total number of cell equivalents tested, gravidity and gestational age at delivery. **Negative binomial regression model adjusted for total number of cell equivalents tested, gravidity, gestational age at delivery and whether fetal microchimerism was detected in the predelivery sample.
Strengths and limitations
Strengths of our study include prospective sample collection and a focus on cellular FMc with targeting of specific nonshared polymorphisms using highly sensitive assays. Our strategy for specific timed collections, prelabour and postdelivery, allowed for comparison of FMc before and after delivery, permitting us to conclude that the change in FMc from predelivery to postdelivery was likely acquired through delivery events, implicating the mode of delivery as an important element in directional cell transfer. Indeed, it has previously been suggested that the majority of cell transfer probably occurs later in gestation, mostly in the peripartum period. 1 In three women, FMc was detected in predelivery samples, but was undetectable in postdelivery samples (Figure 2) . All of these women had a VD. In two of them, the postdelivery sample was collected at an interval that was > 2 standard deviations from the mean of the population, so it is possible that circulating FMc concentrations had fallen to an undetectable level by this time-point. That FMc can be detected in maternal tissues decades after delivery suggests that although these cells may clear the peripheral circulation after delivery, they continue to be harboured in the maternal system in different tissue types. All attempts were made to collect postdelivery samples within 2 hours of placental delivery. Given the variety of maternal and neonatal care needed immediately postpartum and that samples were collected from several hospitals, this was not always feasible. Removal of these two participants from the analysis did not change the findings of our study (results not shown).
Study limitations included a small sample size, and one that did not allow for granularity in CD subtypes, as we grouped scheduled and unscheduled CDs together. Future studies should make an effort to investigate these groups separately. A substantial proportion of incomplete sample sets was initially related to the unpredictable nature of labour and delivery and to physician/nursing hand-offs. This became less frequent with ongoing recruitment following process changes to maximise sample collection. Though detection analysis was clear, our negative binomial regression model results used to evaluate differences in FMc concentration were more complex, with no association of FMc concentration with mode of delivery in the unadjusted model. After adjustment for confounders, including gravidity, the relationship of FMc concentration was similar to the relationship with FMc detection. This discrepancy with the unadjusted negative binomial model was probably due to one outlier in our VD group with gravidity of five and a much higher postdelivery FMc concentration (100.9 gEq/ 10 5 total gEq tested) than other participants. Clinically, this participant's delivery was otherwise unremarkable. It is possible that this participant's higher gravidity contributed to the higher FMc concentration, and hence to the lack of association of FMc with mode of delivery in the unadjusted model. Higher gravidity may be a confounder as multiple pregnancies with the same partner may produce more than one offspring with the unique HLA target used for FMc detection via qPCR. Our group has previously investigated the effect of parity on FMc and maternal Mc suggesting a likely complex relationship with increasing number of potential grafts. 21 One further limitation includes feasibility. By definition, Mc occurs at very low concentrations and so, if more maternal cells were able to be tested, we may have found more cases of detectable FMc in both groups. This probably led to global underestimation of the true occurrence of FMc and would not be expected to differ between groups. Our focus on cellular FMc excludes other compartments that are important for bidirectional communication in pregnancy, including cell-free placental DNA, exosomes, messenger RNA, microRNA and other non-coding RNA. [22] [23] [24] Study of these particles and alterations of their kinetics by mode of delivery and other obstetric factors is warranted. We chose to focus on cellular Mc given its unique role in persistence and potential influence on subsequent maternal health. 9, 23 Figure 2. Fetal microchimerism from predelivery to postdelivery for each participant categorised by mode of delivery. FMc, fetal microchimerism; VD, vaginal delivery; CD, caesarean delivery.
Interpretation
Our findings add to a growing literature on FMc transfer and its role in later life maternal health. Several studies suggest a link between the presence of FMc with either a harmful or a beneficial role in AID status and outcomes. 15, 18, 25 FMc has been found to associate with protection from some diseases, including breast cancer, 10, 11 and may be associated with an overall survival advantage. 26 On the other hand, FMc is associated with other cancers, including colon cancer, 27 and possibly with cardiovascular disease. 26, 28 The relationship of FMc with subsequent disease risk probably depends on numerous factors, several of which are highlighted in observations from studies of the AID rheumatoid arthritis. Rheumatoid arthritis is characterised by female preponderance and increasing incidence in later life 26, 29 along with a nuanced protective association with parity, 30, 31 with the association diminishing as the time interval from the last delivery increases. 25 Although the mechanism underlying this effect is unclear, FMc acquisition has been hypothesised to confer temporary protection that may wane over time, similar to vaccine responses. Pregnancy and parity alone may not explain the complex relationships with AID risk. HLA relationships between maternal and FMc cells may be a contributing factor, suggesting a possible role for fetal genetic material acquired via pregnancy influencing maternal AID risk. 32 That obstetric factors, such as surgical evacuation of early pregnancy, 6 pre-eclampsia 8 and mode of delivery, may influence FMc acquisition is of great interest as it contributes to our understanding of the reproductive origins of disease and warrants consideration in relevant future basic science, epidemiological and clinical studies. In general, persistent FMc may influence subsequent maternal health, and further investigation of fetal-maternal cell transfer is needed to strengthen our understanding of the biological legacy of both early pregnancy events as well as peridelivery factors.
Conclusion
In summary, we found that FMc was more readily detectable and at higher concentrations following CD compared with VD in women undergoing uncomplicated deliveries. Anatomic disruption of the maternal-placental interface or altered immediate maternal postpartum physiology may contribute. FMc in maternal circulation may prove to be an important biomarker for later life maternal health given its association with AID, certain malignancies, and possibly cardiovascular risk. Further research is necessary to evaluate the long-term persistence of FMc cells, their function, and subsequent consequences for long-term maternal health.
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